The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...

A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to ...

Recursion Pharmaceuticals ( RXRX 1.39%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

AI breakthroughs in pharma are pushing Eli Lilly and healthcare stocks higher—and may soon reshape how we fight cancer.

Eli Lilly stock has regained all-time highs, outpacing rivals in the obesity drug market. Click here to read my latest ...

Lexicon Pharmaceuticals targets a turnaround with sotagliflozin, LX9851, pilavapadin, and partnerships offering multiple ...

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

Eli Lilly is partnering with MeiraGTx to develop and commercialize ophthalmology gene therapies, and with SanegeneBio to ...

In today’s Pharmaceutical Executive Daily learn how Novo Nordisk is restructuring leadership to enhance scientific and commercial alignment, ABL Bio secures a major multi-program partnership with Eli ...

Eli Lilly is inking a $100 million-plus biobucks deal with Insilico Medicine in hopes of using artificial intelligence to discover new drugs. | Eli Lilly is inking a $100 million-plus biobucks deal ...

Berkshire Hathaway's diversification, culture, and investment philosophy should still make it a great long-term buy, but ...